Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141284 · ClinicalTrials.gov registry record · Phase 4
An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT00141284 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 12 participants.
The verdict
NCT00141284, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to confirm the safety, efficacy and delineate the pharmacokinetic properties of nelfinavir in HIV/ Hepatitis C coinfected subjects with Child Pugh A compensated cirrhosis and or Hepatic fibrosis
Interventions
- DRUG nelfinavir 1,250 mg twice daily
- DRUG Zidovudine 300 mg twice daily
- DRUG Lamivudine 150 mg twice daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00141284
The ClinicalTrials.gov registry entry for NCT00141284 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which nelfinavir 1,250 mg twice daily is the first listed.
NCT00141284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00141284 about?
NCT00141284 is a clinical study titled "An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C". The purpose of this study is to confirm the safety, efficacy and delineate the pharmacokinetic properties of nelfinavir in HIV/ Hepatitis C coinfected subjects with Child Pugh A compensated cirrhosis and or Hepatic fibrosis
What is the current status of trial NCT00141284?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2005-10. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00141284?
The interventions under investigation include: nelfinavir 1,250 mg twice daily (DRUG), Zidovudine 300 mg twice daily (DRUG), Lamivudine 150 mg twice daily (DRUG).
Who is sponsoring clinical trial NCT00141284?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.